Chordia Therapeutics (190A) · RiskFirst stated

Risk of Development Delays or Discontinuation Due to Uncertainty in Clinical Trials and Regulatory Reviews

First written in FY2024. . Latest entry: FY2024.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Uncertainty over Prolonged or Discontinued Drug Development Pipelines and CommercializationA theme 70 companies write about · 86 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 20 of 41 companies on the "Worse" side.

2 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 70 companies compared. The sentences above are computed from all 70.

Full recordFilings, disclosures and news, newest first

FY2024First statedAnnual report
「If the expected efficacy is not achieved in subsequent clinical trials, serious adverse reactions occur, or approval is not obtained in regulatory review, among other circumstances, research and development may be delayed, the research and development plan may need to be substantially changed, or research and development may have to be discontinued.」
The general risks that efficacy and safety results in clinical trials and regulatory approval may delay, alter or discontinue the development plan were disclosed.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.